



(11) **EP 2 041 159 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(48) Corrigendum issued on:  
**22.02.2012 Bulletin 2012/08**

(45) Date of publication and mention  
of the grant of the patent:  
**28.09.2011 Bulletin 2011/39**

(21) Application number: **07733767.3**

(22) Date of filing: **21.06.2007**

(51) Int Cl.:  
**C07K 5/08** <sup>(2006.01)</sup> **A61K 38/06** <sup>(2006.01)</sup>  
**A61P 31/00** <sup>(2006.01)</sup>

(86) International application number:  
**PCT/GB2007/050346**

(87) International publication number:  
**WO 2007/148135 (27.12.2007 Gazette 2007/52)**

(54) **MACROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS**

MAKROZYKLISCHE VERBINDUNGEN ALS ANTIVIRALE MITTEL

COMPOSES MACROCYCLIQUES EN TANT QU'AGENTS ANTIVIRAUX

(84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR  
HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE  
SI SK TR**

(30) Priority: **23.06.2006 GB 0612423**

(43) Date of publication of application:  
**01.04.2009 Bulletin 2009/14**

(73) Proprietor: **Istituto di Ricerche di Biologia  
Molecolare  
P. Angeletti S.R.L.  
00189 Roma (RM) (IT)**

(72) Inventors:  
• **CRESCENZI, Benedetta**  
**00040 Pomezia (Rome) (IT)**  
• **DONGHI, Monica**  
**00040 Pomezia (Rome) (IT)**  
• **FERRARA, Marco**  
**00040 Pomezia (Rome) (IT)**  
• **GARDELLI, Cristina**  
**00040 Pomezia (Rome) (IT)**  
• **HARPER, Steven**  
**00040 Pomezia (Rome) (IT)**  
• **KOCH, Uwe**  
**00040 Pomezia (Rome) (IT)**

• **ROWLEY, Michael**  
**00040 Pomezia (Rome) (IT)**  
• **SUMMA, Vincenzo**  
**00040 Pomezia (Rome) (IT)**

(74) Representative: **Rollins, Anthony John**  
**Merck & Co., Inc.**  
**Hertford Road**  
**Hoddesdon,**  
**Hertfordshire, EN11 9BU (GB)**

(56) References cited:  
**WO-A-2005/070955 WO-A-2006/119061**  
**WO-A-2007/015787 WO-A-2007/016441**

• **GOUDREAU N ET AL: "The Therapeutic Potential  
of NS3 Protease Inhibitors in HCV Infection"  
EXPERT OPINION ON INVESTIGATIONAL  
DRUGS, ASHLEY PUBLICATIONS LTD.,  
LONDON, GB, vol. 14, no. 9, 2005, pages  
1129-1144, XP003005098 ISSN: 1354-3784**

Remarks:

The file contains technical information submitted after  
the application was filed and not included in this  
specification

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 2 041 159 B8**